Suppr超能文献

接受 CyberKnife 放射外科治疗前庭神经鞘瘤的患者的治疗结果。

Treatment outcomes in patients treated with CyberKnife radiosurgery for vestibular schwannoma.

机构信息

*Department of Otolaryngology-Head and Neck Surgery, and †Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, U.S.A.

出版信息

Otol Neurotol. 2014 Jan;35(1):162-70. doi: 10.1097/MAO.0b013e3182a435f5.

Abstract

OBJECTIVE

To evaluate tumor control, hearing, tinnitus, and balance outcomes of patients treated with CyberKnife (CK) radiosurgery for vestibular schwannoma (VS).

STUDY DESIGN

Retrospective series review.

SETTING

Tertiary referral center.

PATIENTS

All patients treated with CK radiosurgery for vestibular schwannoma by a multidisciplinary radiosurgical team from August 2005 to November 2011. The median age was 59 years, and mean follow-up was 40 months. Seventy-three patients were treated (63 primary radiosurgery and 10 postsurgical).

INTERVENTIONS

CK radiosurgery, serial MRI imaging, comprehensive audiometry, Tinnitus Handicap Inventory (THI) scores, and Activities-Specific Balance Confidence Scale (ABC).

MAIN OUTCOME MEASURES

Tumor control defined as 2 mm linear growth or lower or less than 20% increase in tumor volume (TV), measured in cubic centimeter, after a minimum of 12 months of monitoring, audiogram profiles, THI, and ABC surveys.

RESULTS

Of those treated with CK as primary modality, 83% had 0- to 2-mm growth (tumor control or stable) and 17% grew greater than 2 mm. Of the tumors that were stable, 29% shrank 2 mm or greater. Volumetric analysis found that 74% of tumors had less than 20% TV growth, whereas 26% exhibited 20% or greater increase in TV. Of those deemed stable, 65% shrank 20% or greater TV; 95% of patients did not need additional surgical intervention, 3 required salvage surgery and 1 underwent additional radiosurgery. The majority of patients started with Class D hearing, but of those with Class A or B hearing before treatment, 53.5% maintained serviceable hearing at 3 years of follow-up. The pretreatment and posttreatment median THI Grades were both 1. The pretreatment and posttreatment ABC scores were unchanged at 81%.

CONCLUSION

The LINAC-based CK (18 Gy over 3 fractions at 80% isodose line) provides tumor control rates comparable to other forms of radiosurgery. Analysis for tumor growth was positive for 17% using maximum linear diameters and 26% with a volumetric workstation. This discrepancy is consistent with previous reports where volumetric models were found to be more sensitive in establishing growth. Serviceable hearing was comparable to previous SRS and SRT reports with an overall hearing preservation of 53.5%. This number was 77% in those with pre-Class A hearing. SRS did not affect pretreatment tinnitus or vestibular function.

摘要

目的

评估使用 CyberKnife(CK)放射外科治疗前庭神经鞘瘤(VS)患者的肿瘤控制、听力、耳鸣和平衡结果。

研究设计

回顾性系列研究。

地点

三级转诊中心。

患者

2005 年 8 月至 2011 年 11 月,多学科放射外科小组对所有接受 CK 放射外科治疗的前庭神经鞘瘤患者进行治疗。中位年龄为 59 岁,平均随访时间为 40 个月。共治疗了 73 例患者(63 例为原发性放射外科治疗,10 例为术后治疗)。

干预措施

CK 放射外科治疗、连续 MRI 成像、全面听力测试、耳鸣残疾量表(THI)评分和活动特异性平衡信心量表(ABC)。

主要观察指标

肿瘤控制定义为至少 12 个月监测后肿瘤体积(TV)的线性生长或降低 2 毫米或低于 20%,以立方厘米为单位测量,听力图分析、THI 和 ABC 调查。

结果

在接受 CK 作为主要治疗方式的患者中,83%的患者肿瘤生长在 0-2 毫米之间(肿瘤控制或稳定),17%的患者肿瘤生长超过 2 毫米。在稳定的肿瘤中,29%的肿瘤缩小了 2 毫米或更多。体积分析发现,74%的肿瘤 TV 生长小于 20%,而 26%的肿瘤 TV 生长大于 20%。在被认为稳定的肿瘤中,65%的肿瘤 TV 缩小了 20%或更多;95%的患者不需要额外的手术干预,3 例需要挽救性手术,1 例接受了额外的放射外科治疗。大多数患者开始时听力为 D 级,但在治疗前听力为 A 级或 B 级的患者中,53.5%在 3 年随访时保持了可接受的听力。治疗前和治疗后中位数 THI 分级均为 1。治疗前后 ABC 评分均保持在 81%不变。

结论

基于 LINAC 的 CK(在 80%等剂量线处 3 次分割,每次 18 Gy)提供的肿瘤控制率与其他形式的放射外科治疗相当。使用最大线性直径分析,肿瘤生长的阳性率为 17%,使用体积工作站分析,阳性率为 26%。这种差异与之前的报告一致,在之前的报告中,体积模型在确定生长方面更敏感。可接受的听力与之前的 SRS 和 SRT 报告相当,总体听力保留率为 53.5%。在听力为 A 级之前的患者中,这一比例为 77%。SRS 对治疗前的耳鸣或前庭功能没有影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验